Literature DB >> 15057674

Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.

G Schernthaner1, H-P Kopp, S Ristic, B Muzyka, L Peter, G Mitteregger.   

Abstract

OBJECTIVE: Patients with type 2 diabetes most frequently use injections of premixed insulin formulations twice daily, but intensified insulin therapy may provide better control. This study was designed to compare metabolic control with three daily injections of Humalog Mix50 or premixed human insulin 30/70 (30 % regular/70 % NPH) twice daily in accordance with normal prescription practice. RESEARCH DESIGN AND METHODS: The study cohort of 40 patients with type 2 diabetes used a two-way, crossover design. Patients were randomized to either Mix50 at each main meal or human insulin 30/70 at breakfast and dinner for 3 months, followed by the alternate treatment for 3 months. Blood glucose was measured by the patients at baseline and at the end of each treatment sequence. No significant carryover effects were observed, so treatment sequences were combined and data analyzed by unpaired t-tests.
RESULTS: Mean blood glucose level was significantly (p = 0.010) decreased with Mix50 but not with 30/70 (p = 0.237), and there was a significant difference between treatments at the endpoint (p = 0.035). Fasting blood glucose was increased pre-breakfast and decreased at bedtime with Mix50 but was not significantly changed pre-lunch or dinner or at any time with 30/70 insulin. Blood glucose excursions were significantly decreased with Mix50 after breakfast (p = 0.002), lunch (p < 0.001) and dinner (p = 0.037) but not significantly changed from baseline with 30/70 insulin. The decrease from baseline in HbA (1c) was significantly (p = 0.021) greater with Mix50 than with 30/70 insulin. There were no significant differences between treatments regarding incidence of hypoglycemia or adverse events.
CONCLUSIONS: In patients with type 2 diabetes, a regimen of Humalog Mix50 administered three times daily before meals maintains glucose control more effectively than premixed human insulin 30/70 administered before breakfast and dinner.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057674     DOI: 10.1055/s-2004-814345

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  10 in total

Review 1.  Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.

Authors:  Birgit Fullerton; Andrea Siebenhofer; Klaus Jeitler; Karl Horvath; Thomas Semlitsch; Andrea Berghold; Johannes Plank; Thomas R Pieber; Ferdinand M Gerlach
Journal:  Cochrane Database Syst Rev       Date:  2016-06-30

Review 2.  Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes.

Authors:  Rehan Qayyum; Shari Bolen; Nisa Maruthur; Leonard Feldman; Lisa M Wilson; Spyridon S Marinopoulos; Padmini Ranasinghe; Muhammed Amer; Eric B Bass
Journal:  Ann Intern Med       Date:  2008-09-15       Impact factor: 25.391

3.  Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.

Authors:  Sumeet R Singh; Fida Ahmad; Avtar Lal; Changhua Yu; Zemin Bai; Heather Bennett
Journal:  CMAJ       Date:  2009-02-17       Impact factor: 8.262

4.  Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients.

Authors:  Hiroaki Shimizu; Tsuyoshi Monden; Mihoko Matsumura; Nozomi Domeki; Kikuo Kasai
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

5.  Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus.

Authors:  Birgit Fullerton; Andrea Siebenhofer; Klaus Jeitler; Karl Horvath; Thomas Semlitsch; Andrea Berghold; Ferdinand M Gerlach
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

6.  High-mix insulins.

Authors:  Sanjay Kalra; Mohammad Hamed Farooqi; Ali E El-Houni
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct

7.  Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus.

Authors:  Hiroyuki Ito; Mariko Abe; Shinichi Antoku; Takashi Omoto; Masahiro Shinozaki; Shinya Nishio; Mizuo Mifune; Michiko Togane
Journal:  Drug Des Devel Ther       Date:  2014-04-23       Impact factor: 4.162

8.  A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus.

Authors:  Nozomi Domeki; Mihoko Matsumura; Tsuyoshi Monden; Yuki Nakatani; Yoshimasa Aso
Journal:  Diabetes Ther       Date:  2014-08-27       Impact factor: 2.945

9.  Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort study.

Authors:  J Mamza; R Mehta; I Idris
Journal:  BMJ Open Diabetes Res Care       Date:  2014-05-07

10.  Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.

Authors:  Baptist Gallwitz
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.